Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.
|Videos|August 4, 2021
The Legal Prescription at Pharmacy Times with Ned Milenkovich: State Boards of Pharmacy Part 1
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape.
Advertisement
In The Legal Prescription series with Ned Milenkovich, we discuss a set of important topics in the pharmacy landscape. Our first installment revolves around state boards of pharmacy, such as the purpose of one and the history of how they are created.
Ned Milenkovich, PharmD, J.D., is chair of the Health Care legal practice at Much Law. Ned provides pharmacies, health care providers, drug manufacturers, wholesale distributors, third-party logistics providers, technology companies, and other entities with essential business counseling,transactional, regulatory, government affairs, and litigation services. You can contact Ned with questions at
Advertisement
Related to this article
In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.
Experts on Lp(a) testing, statin myths, cognitive safety, and the 2025-2030 Dietary Guidelines share counseling points from the National Lipid Association's Fall Clinical Lipid Update meeting.
As psychedelic therapies advance through clinical development, pharmacists should prepare for potential roles in their safe, evidence-based integration into patient care.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
In an interview with Pharmacy Times, Ali A. Habib, MD, clinical professor of neurology at the University of California, Irvine, discusses what the hospitalization findings mean for patients and why they should be viewed as supportive evidence
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pneumonic Plague: What Pharmacists Need to Know About Treatment
2
Preparing Pharmacists for Psychedelic Medicine
3
FDA Approves Pritelivir for Refractory HSV Lesions in Immunocompromised Adults
4
FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia
5